Guidelines for management of thyroid cancer in adults: implications for clinical biochemistry

Ann Clin Biochem 2003;40:435-438
doi:10.1258/000456303322326353
© 2003 Association for Clinical Biochemistry

This Article
Right arrow

Full Text (PDF)

Right arrow
Alert me when this article is cited
Right arrow
Alert me if a correction is posted
Services
Right arrow
Email this article to a friend
Right arrow

Similar articles in this journal

Right arrow
Similar articles in PubMed
Right arrow
Alert me to new issues of the journal
Right arrow
Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow
Articles by Beastall, G. H
Right arrow Search for Related Content
PubMed
Right arrow
PubMed Citation
Social Bookmarking

What’s this?

Personal View


Graham H Beastall


Department of Clinical Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK

The implementation of recently published guidelines for themanagement of thyroid cancer in adults should result in improvedclinical outcomes for patients with this condition. A clinicalbiochemist should be part of the support team for the localmultidisciplinary thyroid cancer management team. Serum thyroid-stimulatinghormone assays should have a minimum detection limit of 0.10mU/Lor lower and good baseline security. The measurement of boththyroglobulin and calcitonin is challenging and clinical biochemistsshould have detailed knowledge of the performance characteristicsand limitations of the assays that they report, including thosereferred to a specialist centre, in order to facilitate clinicallyvalid decisions on patient management.


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What’s this?